Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/ Progesterone Receptor (ER/PR) Positive Breast Cancer

Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period.

 

Measure Steward

American Medical Association- convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)

 

Measure Numerator

Patients who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period.

 

Measure Denominator

All female patients aged 18 years and older with a diagnosis of breast cancer with stage IC through IIIC, estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer.